Valuation: Mineralys Therapeutics, Inc.

Market Cap 2.07B 1.85B 1.72B 1.56B 2.95B 200B 2.96B 20.66B 8.09B 102B 7.76B 7.59B 327B P/E 2026 *
-5.21x
P/E 2027 * -9.37x
Enterprise Value 1.84B 1.65B 1.53B 1.39B 2.63B 179B 2.64B 18.45B 7.23B 91.02B 6.93B 6.78B 292B EV / Sales 2026 *
-
EV / Sales 2027 * 21.2x
Free-Float
97.5%
Yield 2026 *
-
Yield 2027 * -
1 day+4.42%
1 week-1.10%
Current month-7.00%
1 month-17.13%
3 months-17.65%
6 months-12.21%
Current year-35.60%
1 week 21.46
Extreme 21.46
23.68
1 month 21.46
Extreme 21.46
29.83
Current year 21.46
Extreme 21.46
37.7
1 year 21.46
Extreme 21.46
47.65
3 years 5.85
Extreme 5.85
47.65
5 years 5.85
Extreme 5.85
47.65
10 years 5.85
Extreme 5.85
47.65
Manager TitleAgeSince
Chief Executive Officer 62 2020-10-31
Director of Finance/CFO 48 2022-02-28
Chief Tech/Sci/R&D Officer 72 2026-08-09
Director TitleAgeSince
Director/Board Member 62 -
Chairman 49 2019-05-30
Director/Board Member 58 2021-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Sell

Chief Executive Officer

-75,000 0.0986%
9/22/26
Catalys Pacific LLC
SellCompany -104,320 0.1371%
9/21/26 Exercice

Chief Commercial Officer

22,314 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
+4.42%-1.10%-44.57%+149.15% 2.07B
-2.59%-5.70%+50.69%+79.01% 70.61B
+3.23%-10.67%+6.27%+53.48% 51.01B
+1.56%+1.17%+8.49%+32.39% 48.1B
+0.39%+0.65%+31.14%+27.04% 42.78B
+0.87%-8.17%+293.37%+643.87% 40.67B
+1.24%-1.01%+10.74%+94.55% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-0.93%-3.79%+47.81%+7.35% 28.16B
+5.32%+0.06%-5.00%-12.60% 24.36B
Average +1.13%-2.50%+40.76%+112.04% 37.86B
Weighted average by Cap. +0.54%-2.93%+51.24%+112.61%

Financials

2026 *2027 *
Net sales - 88.66M 79.18M 73.66M 67M 127M 8.58B 127M 887M 347M 4.37B 333M 326M 14.04B
Net income -383M -342M -318M -289M -546M -37.05B -549M -3.83B -1.5B -18.89B -1.44B -1.41B -60.61B -223M -200M -186M -169M -319M -21.63B -320M -2.23B -876M -11.03B -839M -821M -35.39B
Net Debt -221M -198M -184M -167M -316M -21.42B -317M -2.21B -867M -10.92B -831M -813M -35.04B -189M -169M -157M -143M -269M -18.28B -271M -1.89B -740M -9.32B -709M -694M -29.9B
Projected Income Statement - Annual - Mineralys Therapeutics, Inc.
Logo Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.
Employees
76
Date Price Change Volume
26-10-09 US$23.37 +4.42% 895,314
26-10-08 US$22.38 +1.31% 2,245,272
26-10-07 US$22.09 +0.64% 989,115
26-10-06 US$21.95 -5.79% 1,215,986
26-10-05 US$23.30 -1.40% 1,079,138
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Mineralys Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.37USD
Average target price
48.50USD
Spread / Average Target
+107.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mineralys Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MLYS Stock